TickerFacts.

Zhengye Biotechnology Holding Ltd (ZYBT): Revenue

Annual figures by period end, from SEC filings.

116.36M CNY
Year ended 2025-12-31
-23.5%
3-year compound annual growth
260.27M CNY2022-12-31: 260.27M CNY2023-12-31: 211.65M CNY2024-12-31: 186.36M CNY2025-12-31: 116.36M CNY116.36M CNY
2022-12-31 Revenue (CNY) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31116.36M CNY-37.6%2026-04-28, From 2025-01-01
2024-12-31186.36M CNY-12.0%2026-04-28, From 2024-01-01
2023-12-31211.65M CNY-18.7%2026-04-28, From 2023-01-01
2022-12-31260.27M CNYn/a2025-07-03, From 2022-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Zhengye Biotechnology Holding Ltd (ZYBT)2025-12-31116.36M CNY-37.6%
Yatsen Holding Ltd (YSG)2025-12-314.30B CNY+26.7%

Compare ZYBT, YSG side by side · Screen every company in Pharmaceutical Preparations ↗